ストックスクリーナーアプリを入手
284.57
0.83%
-2.38
プレマーケット:
277.53
-7.04
-2.47%
Krystal Biotech Inc (KRYS) 最新ニュース
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus - sharewise.com
Krystal Biotech Q1 2026 Earnings Call Transcript - Sahm
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results - Benzinga
Krystal Biotech Q1 2026 earnings preview - MSN
Krystal Biotech stock hits all-time high at 301.99 USD - Investing.com
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2026 Earnings Call Transcript - Insider Monkey
A Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum - Yahoo Finance
Krystal Biotech Earnings Call Highlights Profitable Growth - TipRanks
Krystal Biotech Reports Strong Q1 2026 Earnings with VYJUVEK Gro - GuruFocus
Krystal Biotech jumps as Q1 results show strong VYJUVEK growth and upbeat pipeline/regulatory updates - Quiver Quantitative
Krystal Biotech Jumps 5.3% Amid Sector-Wide Rally - AlphaStreet
Why Is Krystal Biotech (KRYS) Jumping 5.2%? - AlphaStreet
Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end - MSN
Krystal Biotech Releases Q1 2026 Financial Results - AlphaStreet
Krystal Biotech, Inc. Reports Strong Q1 2026 Financial Results with $116 Million Revenue and Significant Net Income Growth - Minichart
Krystal (KRYS) Q1 2026 Earnings Transcript - The Globe and Mail
Krystal Biotech, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Krystal Biotech : First Quarter 2026 Earnings Call - marketscreener.com
KRYS: Q1 2026 delivered robust revenue and EPS growth, with expanding global VYJUVEK sales - TradingView
BofA cuts Krystal Biotech stock price target on revenue mix shift By Investing.com - Investing.com Australia
Krystal Biotech Reports Strong Q1 2026 Results: $116.4M VYJUVEK Revenue, Pipeline Advancements, and $1B Cash Reserves - Minichart
Krystal (KRYS) Q1 2025 Earnings Transcript - The Globe and Mail
Krystal Biotech, Inc. (KRYS) tops Q1 earnings and revenue estimates - MSN
BofA cuts Krystal Biotech stock price target on revenue mix shift - Investing.com UK
KRYS: Q1 revenue rose 32% to $116.4M, with robust margins and major clinical milestones ahead - TradingView
Krystal Biotech (KRYS) Projects FY26 R&D and SG&A Expenses of $1 - GuruFocus
Krystal Biotech Q1 Earnings Call Highlights - Yahoo Finance
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Transcript : Krystal Biotech, Inc., Q1 2026 Earnings Call, May 04, 2026 - marketscreener.com
KRYS: Q1 revenue grew 32% year-over-year to $116.4M, with robust VYJUVEK sales and 95% gross margin - TradingView
Earnings call transcript: Krystal Biotech Q1 2026 beats earnings expectations By Investing.com - Investing.com Canada
Krystal Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Krystal Biotech (KRYS) Reports Strong Q1 Revenue, CEO Highlights Growth Momentum - GuruFocus
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
KRYSTAL BIOTECH ($KRYS) Releases Q1 2026 Earnings - Quiver Quantitative
Krystal Biotech stock rises over 6% on earnings beat and strong revenue By Investing.com - Investing.com South Africa
Krystal Biotech stock rises over 6% on earnings beat and strong revenue - Investing.com
Krystal Biotech reports $116.4M in sales as key eye study fills - Stock Titan
Earnings Flash (KRYS) Krystal Biotech Posts Q1 EPS $1.83, vs. FactSet Est of $1.44 - marketscreener.com
Krystal Biotech (NASDAQ: KRYS) spouses report 11.5% stake - Stock Titan
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q1 Revenue $116.4M, vs. FactSet Est of $112.1M - marketscreener.com
Krystal Biotech (KRYS) grows VYJUVEK sales 32% and advances late-stage gene therapy pipeline - Stock Titan
Strong VYJUVEK sales lift Krystal Biotech (NASDAQ: KRYS) Q1 profit - Stock Titan
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results - marketscreener.com
BRIEF-Krystal Biotech Q1 Net Income USD 55.932 Million - TradingView
What Krystal Biotech (KRYS)'s RMAT Win for KB707 in Lung Cancer Means For Shareholders - Sahm
Krystal Biotech (KRYS) Valuation Check After Strong One Year Shareholder Returns - Sahm
Trading the Move, Not the Narrative: (KRYS) Edition - Stock Traders Daily
How The Krystal Biotech (KRYS) Narrative Is Shifting With Vyjuvek And Late Stage Pipeline - Yahoo Finance
Krystal Biotech (KRYS) Q1 2026 Preview: EPS Est. $1.42, Reports May 4 - AlphaStreet
All eyes on Krystal Biotech earnings amid pipeline expansion - Investing.com UK
All eyes on Krystal Biotech earnings amid pipeline expansion By Investing.com - Investing.com Australia
Krystal Biotech, Inc. (KRYS) earnings expected to grow: What to know ahead of next week's release - MSN
Krystal Biotech to Present at Upcoming Scientific Conferences - The Manila Times
Krystal Biotech lines up May talks on cystic fibrosis, lung cancer - Stock Titan
Pictet Asset Management Holding SA Sells 40,336 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
High Growth Tech Stocks To Watch In The US April 2026 - simplywall.st
Vanguard Portfolio Management (KRYS) Discloses 5.05% Holding in Krystal Biotech - Stock Titan
Earnings Preview: KRYS to Report Financial Results Pre-market on May 04 - Moomoo
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):